|
| General Information |
| Business: |
We are a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on our proprietary technology platform called Arcelis. Our most advanced product candidate is AGS-003, which we are developing for the treatment of metastatic renal cell carcinoma, or mRCC, and other cancers. We are currently enrolling patients in a pivotal phase 3 clinical trial of AGS-003 in combination with sunitinib (Sutent) for the treatment of mRCC under a special protocol assessment, or SPA, with the Food and Drug Administration, or FDA. The primary endpoint of the phase 3 clinical trial is overall survival. In our phase 2 clinical trial of AGS-003 in combination with sunitinib in mRCC patients, median overall survival was 30.2 months. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
94 |
Founded: |
1997 |
|
| Contact Information |
| Address: |
4233 Technology Drive Durham, NC, 27704 , US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 5.3 mil (last 12 months) |
|
| Net Income: |
$ -18.5 mil (last 12 months) |
|
| IPO Profile |
|
|
|
|
